2022 Annual Meeting | C166 - Clinical EMG 2: Case-based Clinical Applications of Nerve Conduction Studies and Needle Electromyography

Date Thursday 04/07/22

Time 03:30 PM - 05:30 PM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Ruple S. Laughlin, MD, FAAN

Topic(s) Neuromuscular and Clinical Neurophysiology (EMG)

Learning Objectives Participants should be able to demonstrate how to approach a neuromuscular patient electrodiagnostically and utilize nerve conduction studies and needle examination to evaluate suspected peripheral neuropathy, myopathy, radiculopathies, and neuromuscular junction disorders.This program complements Clinical EMG 1: Principles and Practice of NCS and Needle EMG but covers independent topics.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider

Teaching Styles Case-based, Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
03:30 PM - 03:35 PM PDT	Introduction	Introduction Ruple S. Laughlin, MD, FAAN
03:30 PM - 03:30 PM PDT	Speaker	Walk-in Slides Ruple S. Laughlin, MD, FAAN
03:35 PM - 04:10 PM PDT	Speaker	Case-Based EDX Applications in Neuropathy Ruple S. Laughlin, MD, FAAN
04:10 PM - 04:50 PM PDT	Speaker	Case-Based EDX Applications: Radiculopathy and Plexopathy Devon I. Rubin, MD, FAAN
04:50 PM - 05:20 PM PDT	Speaker	Case-Based EDX Application: NMJ and Myopathy Kelly G. Gwathmey, MD
05:20 PM - 05:30 PM PDT	Q&A	Questions and Answers

Faculty Disclosures
Devon I. Rubin, MD, FAAN	Dr. Rubin has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Clinical Neurophysiology. Dr. Rubin has received intellectual property interests from a discovery or technology relating to health care. Dr. Rubin has received intellectual property interests from a discovery or technology relating to health care. Dr. Rubin has received publishing royalties from a publication relating to health care. Dr. Rubin has received publishing royalties from a publication relating to health care.
Ruple S. Laughlin, MD, FAAN	Dr. Laughlin has nothing to disclose.
Kelly G. Gwathmey, MD	Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Strongbridge. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Gwathmey has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion Pharmaceuticals.

��ɫ��

��ɫ��